LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more
LegoChem Biosciences Inc (141080) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.022x
Based on the latest financial reports, LegoChem Biosciences Inc (141080) has a cash flow conversion efficiency ratio of -0.022x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.15 Billion) by net assets (₩563.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LegoChem Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how LegoChem Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LegoChem Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LegoChem Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VSE Corporation
NASDAQ:VSEC
|
0.024x |
|
Addsino Co Ltd
SHE:000547
|
0.039x |
|
ONDAS HLDGS INC. DL-0001
F:1B8
|
N/A |
|
Huaxin Cement Co Ltd A
SHG:600801
|
0.044x |
|
Haci Omer Sabanci Holding AS
IS:SAHOL
|
-0.131x |
|
Kobe Bussan Co. Ltd.
PINK:KOBNF
|
0.018x |
|
Brady Corporation
NYSE:BRC
|
0.041x |
|
Humanwell Healthcare Group Co Ltd
SHG:600079
|
0.042x |
Annual Cash Flow Conversion Efficiency for LegoChem Biosciences Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of LegoChem Biosciences Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩616.00 Billion | ₩78.48 Billion | 0.127x | +130.34% |
| 2023-12-31 | ₩148.22 Billion | ₩-62.24 Billion | -0.420x | -1192.20% |
| 2022-12-31 | ₩219.60 Billion | ₩-7.14 Billion | -0.032x | +80.00% |
| 2021-12-31 | ₩258.77 Billion | ₩-42.05 Billion | -0.162x | -22.33% |
| 2020-12-31 | ₩112.13 Billion | ₩-14.89 Billion | -0.133x | -162.66% |
| 2019-12-31 | ₩113.75 Billion | ₩24.11 Billion | 0.212x | +268.92% |
| 2018-12-31 | ₩101.66 Billion | ₩-12.76 Billion | -0.125x | +26.34% |
| 2017-12-31 | ₩48.21 Billion | ₩-8.21 Billion | -0.170x | +21.52% |
| 2016-12-31 | ₩60.06 Billion | ₩-13.04 Billion | -0.217x | -9.73% |
| 2015-12-31 | ₩43.18 Billion | ₩-8.54 Billion | -0.198x | +49.69% |
| 2014-12-31 | ₩20.04 Billion | ₩-7.88 Billion | -0.393x | -- |